Patents by Inventor Aude JAFFRE

Aude JAFFRE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240425863
    Abstract: Ischemic conditions are a leading cause of death for both men and women, Ischemia, a condition characterized by reduced blood flow and oxygen to an organ. Re-establishment of blood flow, or reperfusion, and re-oxygenation of the affected area following an ischemic episode is critical to limit irreversible damage. However, reperfusion also associates potentially damaging consequences. For instance, increased vascular permeability is an important contributor to edema and tissue damage following ischemic events. Here the inventors shows that genetic inhibition of PI3K-C2? reduces cerebral infarction in two ischemic/reperfusion (I/R) models and improves neurological outcome. The genetic inhibition stabilizes the blood-brain barrier (BBB) after ischemic stroke and reduces inflammation.
    Type: Application
    Filed: April 12, 2024
    Publication date: December 26, 2024
    Inventors: Marie-Pierre GRATACAP, Jean DARCOURT, Bart VANHAESEBROECK, Gaëtan CHICANNE, Bernard PAYRASTRE, Vincent LARRUE, Romain SOLINHAC, Aude JAFFRE, Denis VIVIEN, Typhaine ANQUETIL
  • Patent number: 12123000
    Abstract: Ischemic conditions are a leading cause of death for both men and women. Ischemia, a condition characterized by reduced blood flow and oxygen to an organ. Re-establishment of blood flow, or reperfusion, and re-oxygenation of the affected area following an ischemic episode is critical to limit irreversible damage. However, reperfusion also associates potentially damaging consequences. For instance, increased vascular permeability is an important contributor to edema and tissue damage following ischemic events. Here the inventors shows that genetic inhibition of PI3K-C2? reduces cerebral infarction in two ischemia/reperfusion (I/R) models and improves neurological outcome. The genetic inhibition stabilizes the blood-brain barrier (BBB) after ischemic stroke and reduces inflammation.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: October 22, 2024
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PAUL SABATIER TOULOUSE III, UNIVERSITY COLLEGE LONDON, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE, UNIVERSITE DE CAEN NORMANDIE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE CAEN
    Inventors: Marie-Pierre Gratacap, Jean Darcourt, Bart Vanhaesebroeck, Gaëtan Chicanne, Bernard Payrastre, Vincent Larrue, Romain Solinhac, Aude Jaffre, Denis Vivien, Typhaine Anquetil
  • Publication number: 20230287430
    Abstract: Ischemic conditions are a leading cause of death for both men and women. Ischemia, a condition characterized by reduced blood flow and oxygen to an organ. Re-establishment of blood flow, or reperfusion, and re-oxygenation of the affected area following an ischemic episode is critical to limit irreversible damage. However, reperfusion also associates potentially damaging consequences. For instance, increased vascular permeability is an important contributor to edema and tissue damage following ischemic events. Here the inventors shows that genetic inhibition of PI3K-C2? reduces cerebral infarction in two ischemia/reperfusion (I/R) models and improves neurological outcome. The genetic inhibition stabilizes the blood—brain barrier (BBB) after ischemic stroke and reduces inflammation.
    Type: Application
    Filed: November 15, 2022
    Publication date: September 14, 2023
    Inventors: Marie-Pierre GRATACAP, Jean DARCOURT, Bart VANHAESEBROECK, Gaëtan CHICANNE, Bernard PAYRASTRE, Vincent LARRUE, Romain SOLINHAC, Aude JAFFRE, Denis VIVIEN, Typhaine ANQUETIL
  • Publication number: 20210238605
    Abstract: Ischemic conditions are a leading cause of death for both men and women. Ischemia, a condition characterized by reduced blood flow and oxygen to an organ. Re-establishment of blood flow, or reperfusion, and re-oxygenation of the affected area following an pot ischemic episode is critical to limit irreversible damage. However, reperfusion also associates potentially damaging consequences. For NI instance, increased vascular permeability is an important contributor to edema and tissue damage following ischemic events. Here the inventors shows that genetic inhibition of PI3K-C2? reduces cerebral infarction in two ischemia/reperfusion (UR) models and improves neurological outcome. The genetic inhibition stabilizes the blood-brain barrier (BBB) after ischemic stroke and reduces inflammation.
    Type: Application
    Filed: June 14, 2019
    Publication date: August 5, 2021
    Inventors: Marie-Pierre GRATACAP, Jean DARCOURT, Bart VANHAESEBROECK, Gaëtan CHICANNE, Bernard PAYRASTRE, Vincent LARRUE, Romain SOLINHAC, Aude JAFFRE, Denis VIVIEN, Typhaine ANQUETIL